Table 2.
Tumor response to Rh-endostatin plus irinotecan/cisplatin.
| Response | Patients (N = 50) |
|---|---|
| Best objective response | |
| Complete response | 0 |
| Partial response | 13 (26%; 16-40) |
| Stable disease | 18 (36%; 24-50) |
| Progressive disease | 15 (30%; 19-44) |
| Not evaluablea | 4 (8%; 3-19) |
| Objective responseb | 13 (26%; 16-40) |
| Disease controlc | 31 (62%; 48-74) |
Data were expressed as n (%; 95% CI).
a
Patients had no valid postbaseline response assessments.
b
Objective response = complete response plus partial response.
c
Disease control = complete response plus partial response plus stable disease.